Summary

A new era in the treatment of hemophilia has emerged with a new generation of protein therapeutics. This article provides an overview of the future of coagulation factor replacement therapy. Protein engineering has increased the clinical potential and reduced rapid clearance of antihemophilic drugs from the body. Current therapy for hemophilia is safe and effective but immunogenic. Next generation antihemophilic drugs should have enhanced efficacy, greater safety, reduced immunogenicity, and improved delivery.

  • Hematology Clinical Trials
  • Hemorrhagic Disorders
  • Hematology
  • Hematology Clinical Trials
  • Hemorrhagic Disorders
View Full Text